NEW YORK--(BUSINESS WIRE)--Foresight Biotherapeutics, Inc. today announced data from a pre-clinical study will be presented at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held in Ft. Lauderdale, Florida. The study was designed to assess the safety and efficacy of the topical administration of FST-100 in a widely accepted rabbit model of adenoviral conjunctivitis. FST-100 is the company’s lead product for the treatment of adenoviral conjunctivitis. The results demonstrated a statistically significant effect in both clinical cure and adenoviral eradication. The work was conducted at the Louisiana State University (LSU) Health Sciences Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues. Detailed data are being presented at a poster discussion session on Wednesday, May 5th at 8:30am-10:15am.
